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ABSTRACT 
Backgrounds 
There is a paucity of studies on cutaneous sarcoidosis in the South African setting, with the 
last study published 18 years ago. More studies are needed to explore these gaps to inform 
referral policy and guidelines for early diagnosis and management of cutaneous sarcoidosis in 
the country. 
 
Objectives  
The study focuses on the patterns of cutaneous sarcoidosis, demographic features, and 
histological associations with the clinical patterns of skin sarcoidosisfound in patients with 
sarcoidosis presenting to the dermatology outpatient clinic at the Chris Hani Baragwanath 
Academic hospital. In addition, the pattern, chronicity and severity of the cutaneous 
manifestations were described.  Furthermore, the co-existence of HIV/AIDS and sarcoidosis 
was also examined. 
Methods 
A retrospective descriptive studythat spans from 1991 to 2015, was carried out which 
included cases that had a definitive diagnosis of sarcoidosis. One hundred case records of 
patients with cutaneous sarcoidosis that attended the Dermatology Outpatient Clinic, from the 
study site in Soweto, in the south of Johannesburg, were collected and transferred to a 
collection data sheet. 
Results  
In this predominantly Black African population, women above 45 years old (70%), were most 
commonly affected. Papules (68.8%) and plaques (27.1%) were the most frequent skin 
findings in Black Africans.  The most frequent extra-cutaneous organ affected was the lung 
(53%). Subcutaneous lesions were found to be significantly associated (p-value <0. 012) with 
Scadding stage 0 and stage 4 lung involvement. On histology 70% of the cases had clean 
granulomas, frequently associated with papules clinically. HIV seropositive and sarcoidosis 
cases demonstrated an inversely proportional association with the CD4 count, with disease 
progression noted with CD4 increments after initiation of therapy. 
Conclusion 
The variations in the patterns of presentation revealed in this study can improve our knowledge of 
cutaneous patterns of sarcoidosis in this study population and assist with the development of 
prompt diagnosis and early treatment intervention.  
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DEFINITION OF KEY CONCEPTS 
The terms and concepts identified as being central to the research topic are defined below: 
• Sarcoidosis: In Greek, sarco means "flesh," eidos means "like," and osis means 
"condition"; thus, flesh-like condition (72). 
• Cutaneous sarcoidosis lesions: Eruptions caused by sarcoidosis are classified as 
“specific” (non-caseating granulomas are present in biopsy specimens) or “non-
specific” (lesions develop as a result of a reactive process without the formation of 
granuloma) (32) 
• ACCESS: A Case Control Etiological Study Of Sarcoidosis was designed by 
Baughman and his colleagues to study the aetiology of sarcoidosis. Judson and 
colleagues later updated the instrument used to define the diagnostic criteria for 
sarcoidosis, in 2014 (WASOG sarcoidosis organ assessment instrument). 
According to this instrument, prerequisites for the acceptance that an organ is involved 
by sarcoidosis were  (1) histological features of granulomatous inflammation without 
a known cause in another organ; (2) exclusion of other causes for the clinical 
manifestations. These clinical manifestations were further classified as being due to 
sarcoidosis according to the following definitions: (i) highly probable (≥ 90% 
likelihood), (ii) probable (50 - 90% likelihood), (iii) possible (< 50% likelihood).  
• HIV infection: infection by the Human Immunodeficiency Virus as diagnosed by a 
positive HIV antibody test, confirmed by a second HIV antibody test. 
• HAART: highly active anti-retroviral therapyis defined as treatment with three or more 
antiretroviral agents, including a protease inhibitor. 
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CHAPTER ONE 
1.1 INTRODUCTION 
1.1.1 Historical background 
The first dermatological presentation of sarcoidosis was described in the 19th century in 1875 
by Hutchinson, a physician of English descent.  The clinical pattern he described was that of a 
patient who presented with multiple, raised, purplish skin patches which had appeared over a 
two year period. In 1899, Caesar Boeck, a nephew to a Norwegian dermatologist, reported the 
cutaneous histology of these lesions.  The skin lesions resembled a sarcoma but they were 
benign clinically and histologically.  Boeck then coined the term ‘sarkoid’ and the word 
sarcoidosis stemmed from this report  (1, 2).  It was previously considered as an isolated skin 
disease entity, but over the past two centuries, it became clear that sarcoidosis affects multiple 
organs  (3-5).  Table 1.1 shows the systems involved in order of frequency. 
 
Table 1.1 Systemic manifestations of sarcoidosis (adapted from Haimovic et al. 2012 (71)) 
 
 
 
 
 
 
 
 
 
 
 
 
Extra-cutaneous 
organ involvement 
Frequency (%) Comment 
Respiratory system 95% Most commonly involved 
organ 
Cutaneous 15 -25 Erythema nodosum, plaques 
subcutaneous nodules, lupus 
pernio 
Lymph nodes 15 -30 (hilar 90%) Firm non-tender 
Ophthalmic system 12 65% anterior uveitis 
Hepatic 12 Granulomas in 40 – 70% 
Neurological system 5 -10 Facial nerve palsy most 
common 
Bone marrow 4 – 20 Anaemia and leukopaenia 
Metabolic 4 -11 Hypercalciuria 40%, renal 
stones 10% 
Cardiac  5- 10 75% diagnosed at autopsy 
Bone/joint  0.5 Joint 25 -40% 
Muscle 0.4  
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1.1.2 Sarcoidosis 
Sarcoidosis is a multi-systemic granulomatous disorder of unknown aetiology  (6). It is 
characterised by heterogeneous clinical features of which the respiratory system is commonly 
affected with an estimated frequency of 95%, followed by cutaneous  involvement in up to 
25% of cases  (6-8). According to Baughman et al., African American patients have an 
increased incidence of cutaneous sarcoidosis compared to the Caucasian population, and a 
higher prevalence of skin manifestations of sarcoidosis occurs in females  (9-11). 
 
There has been a change in the age of diagnosis demonstrated in recent epidemiologic studies, 
with the investigators finding a shift in the peak incidence to 40 – 59 years  (13, 14).  A study 
conducted over three decades at Groote Schuur Hospital in Cape Town demonstrated a 
prevalence rate of sarcoidosis of 17/100000 in the Coloured population, 27/100000 in the 
Black and 6/100000 in White population  (15).  Many studies have reported a higher 
incidence of sarcoidosis in females  (13, 15-17). However, a few reports did not find any 
gender preference  (13, 18).  A South African study of 110 cases conducted in Cape Town 
over a 7 year period with 71 Coloured, 25 Black African, and 14 Caucasians described a 
discrepancy in gender distribution with 2:1 female to male ratio in the Coloured population 
contrary to the other racial groups (1:1 in both Black African and White populations) (19).  
The findings were attributed to demographic bias, as the population of the Cape Peninsula at 
that time consisted of 610 215 Coloureds, 378 505 Whites and 107 877 Black Africans.  A 
familial tendency was observed among the African American population with cutaneous 
sarcoidosis (9, 20). 
 
1.1.3 Cutaneous sarcoidosis 
Overall, skin manifestations occur in 20-35% of the patients diagnosed with sarcoidosis, and 
occur mainly at the onset of the disease  (12).  Isolated cutaneous lesions have been reported 
in about a third  of the patients with sarcoidosis  (3, 12), which are subsequently followed by 
extra-cutaneous systemic involvement over a period of four weeks to twelve months  (3). Skin 
manifestations of sarcoidosis may appear at any age with peaks observed between ages 20 to 
40 years  (10).  Studies on cutaneous sarcoidosis in South Africa are limited.  
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Having worked as a registrar at the CHBH, in Soweto, Johannesburg, the researcher noticed 
the lack of guidelines and protocols to assist with the diagnosis of cutaneous sarcoidosis and 
treatment options.  Because the disease has no specific aetiological source and presents with 
variable clinical patterns and an unpredictable course, it is difficult to define a specific 
management strategy.  It is important to conduct a study to review the clinical spectrum of 
cutaneous sarcoidosis in the African context so as to improve on the identification of specific 
clinical patterns reported on in Africa and enhance treatment interventions. 
 
1.1.4 Problem Statement 
Sarcoidosis is a multi-organ disorder characterized by non-caseating granulomas of unknown 
aetiology (6).  Cutaneous manifestations occur in 20-35% of cases of sarcoidosis  (12, 21-24).  
Cutaneous sarcoidosis often develops as an isolated organ involvement  (3) or in combination 
with multi-organ involvement  (12, 25). 
 
Although female predominance of cutaneous sarcoidosis appears to be consistent across 
ethnic groups, some variations in the gender ratio of cases across ethnic groups have been 
observed.  Percentages of female patients with sarcoidosis reported in different continents are 
listed as follows: 68% in America; 74% in Northern Europe; 77% in Southern Europe; 81% in 
Northern Asia and 83% in sub-Saharan Africa  (12, 17, 21, 22, 24). Other authors reported no 
gender preference  (13, 18).  The African American/ Black African female population, is the 
racial group mostly affected by cutaneous sarcoidosis  (12, 17, 21, 22, 24).  an American  
author conducted a study on a military veteran population which was racially heterogeneous 
and found the highest incidence of cutaneous sarcoidosis in female African Americans (29 
versus 12 Caucasian females) (9, 19).  Differences in recruitment of study populations may 
influence reported gender demographics. 
 
The impact of HIV/AIDS on patterns of presentation of cutaneous sarcoidosis and the 
influence of demographics is an additional goal of this study. With a period of 18 years where 
no reviews of the condition were done in South Africa, there is justification for a new study to 
further understand the pattern of presentation, severity, and histopathology of cutaneous 
sarcoidosis.  Access to medical care, which was easily open to the White population in the 
past and less so to Black South Africans, might have had a significant influence on the 
apparent incidence, the clinical spectrum of cutaneous sarcoidosis and the subsequent severity 
and chronicity described in the South African literature.  This lack of access could have 
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contributed to the reported late presentation and advanced nature of cutaneous sarcoidosis in 
the Black Africans, hence giving rise to the notion that the spectrum of cutaneous sarcoidosis 
is more florid amongst African Americans and Black Africans  (17).  Interestingly Rybicki, an 
American author, conducted a series of studies to determine the familial and probable genetic 
link of cutaneous sarcoidosis in African American and /or Black African race  (9, 20).  
Together with his colleagues, Rybicki attempted to confirm reports of sarcoidosis in first-
degree relatives of cases and controls by personal interviews, concluding that familial 
associations were a risk factor for cutaneous sarcoidosis.   He also concluded from his 
findings that increased surveillance of relatives for cases of sarcoidosis cases is probably not 
warranted, given the small percentage (1%) in whom it will eventually develop  (20). 
 
Dermatologists are often the first clinicians to examine and define skin lesions, but thoracic 
physicians or rheumatologists publish many reports on cutaneous sarcoidosis, especially in 
poorly resourced countries. 
 
Florid and nonspecific atypical cutaneous manifestations of sarcoidosis (e.g. hypo-pigmented 
and ichthyosiform lesions, mutilating disfiguring chronic lesions) area ssociated more 
commonly with non-Caucasians (11, 26).  In South Africa, there is a paucity of literature 
examining the spectrum and the management of cutaneous sarcoidosis.  This study prompts a 
fresh review of this topic amongst Black South Africans. 
 
1.1.5 Significance of the study 
Epidemiological data on the incidence, trends, presentations, severity and treatment outcomes 
could inform the development of protocols for prompt diagnosis and early management 
intervention at the Dermatology Outpatient Clinic at Chris Hani Baragwanath Academic 
Hospital.  Findings from this study will add to the limited knowledge of cutaneous sarcoidosis 
in South Africa.  
 
1.1.6 Aim of the study 
The overall aim of the study was to evaluate the spectrum of cutaneous manifestations of 
sarcoidosis at Chris Hani Baragwanath Academic Hospital Dermatology outpatient clinic. 
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1.1.7 Objectives 
In order to provide direction for the study, the following objectives were formulated: 
i. To examine the correlations between demographic characteristics and cutaneous   
manifestations of sarcoidosis. 
ii. To describe the pattern, severity and chronicity of cutaneous manifestations of 
sarcoidosis in patients attending the Dermatology outpatient clinic at the Chris Hani 
Baragwanath Academic Hospital. 
iii. To describe the histopathological findings of biopsy specimens of cutaneous lesions of 
sarcoidosis in the cohort. 
iv. To identify any association between HIV and cutaneous or systemic sarcoidosis. 
 
1.1.8 Research Questions 
The study will address the following questions: 
i. Are there correlations between demographic characteristics and cutaneous   
manifestations of sarcoidosis in patients managed at Chris Hani Baragwanath 
Academic Hospital? 
ii. What are the patterns, severity and chronicity of cutaneous manifestations of 
sarcoidosis in patients attending the outpatient clinic at Chris Hani Baragwanath 
Academic Hospital? 
iii. What are the histopathological findings of biopsy specimens of cutaneous lesions of 
sarcoidosis in the cohort? 
iv. Is there any association between HIV and cutaneous or systemic sarcoidosis? 
 
1.1.9. Chapter layout 
Chapter 1: This chapter covers the protocol for the study and also provides in-depth 
literature review on cutaneous sarcoidosis, and an appraisal of studies done globally, 
in sub-Saharan Africa and South Africa. The existing gaps in the literature are 
identified, thus, providing appropriate context for the new study.  
Chapter 2: This chapter highlights the methodology employed in carrying out the 
study. 
Chapter 3: This chapter provides the results, using tables, flow diagrams and graphs. 
Chapter 4: This chapter discusses the findings of the study, limitations of the study 
and conclusion. 
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1.1.10. Conclusion 
Cutaneous sarcoidosis with its protean clinical manifestations has an unpredictable natural 
course (2).  Review of the literature has revealed a paucity of studies examining the spectrum 
and management of cutaneous sarcoidosis in South Africa.  More studies are needed to 
explore these gaps to inform referral policy and guidelines for early diagnosis and 
management of cutaneous sarcoidosis in the country.  The next chapter appraises the existing 
literature on cutaneous sarcoidosis globally, regionally and in South Africa. 
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1.2LITERATURE REVIEW 
1.2.1. Introduction 
This section is designed to provide a review of what is currently known about the research 
topic and areas surrounding it.  An overview of the current global trends of sarcoidosis and 
the cutaneous patterns of presentation with particular emphasis on the South African context 
will be presented.  The factors that may have an influence on the cutaneous sarcoidosis 
spectrum in South Africa are discussed.  The last review of this topic was published in 1999, 
and prompted the author’s review. A commentary on the co-existence of HIV/AIDS and 
cutaneous sarcoidosis is also included.   
1.2.2. Literature Search Strategy 
A search of published literature was conducted using PubMed, Clinical Key, Scopus, South 
African ePublications and Google Scholar. Keywords used in a variety of combinations were: 
Cutaneous Sarcoidosis, Clinical patterns of cutaneous sarcoidosis; cutaneous sarcoidosis in 
sub-Saharan Africa; co-existence of HIV/AIDS and sarcoidosis.  The websites of the National 
Health Laboratory Service (NHLS) and Statistics South Africa (Stats SA) were also searched 
for relevant information.  Electronic journals were accessed using the University of the 
Witwatersrand and the Walter Sisulu University online facility. All the articles retrieved were 
in English.  
1.2.3. Clinical manifestations and Trends in the epidemiology 
i. Definition 
Sarcoidosis is a multi-organ granulomatous disorder with no known cause  (6). This disease 
has variable clinical manifestations, with the skin as the second most frequently affected 
organ (20 - 35% of the cases on average) (3), preceded only by the respiratory system  (3, 14, 
27).  A table (Table 1.1) highlights a list of other organs affected in order of frequency. The 
skin manifestations of sarcoidosis are categorized as “specific” (non-caseating granuloma 
present in biopsy specimen of tissue) or “nonspecific” (lesions develop as a result of a 
reactive process) (Table1.2)  (4).  Race, age and gender have an influence on the 
manifestations of sarcoidosis, resulting in variations in incidence (28, 29).  A number of 
studies show that the presence or absence of granulomatous cutaneous involvement has no 
prognostic significance (30, 21). 
 
8 
 
 
Table 1.2 Cutaneous Manifestations Of Sarcoidosis (adapted from Heath et al. 2012 (11)) 
Specific skin lesions  Non-specific skin 
lesions 
Distinct lesions Non-distinct lesions Erythema nodosum 
Papules  Subcutaneous nodules 
Calcification 
Plaques Hypopigmented macules Prurigo 
Lupus pernio Ulcerative sarcoidosis Dactylitis 
Scar sarcoidosis Psoriasiform lesions  
 Alopecia and nail sarcoidosis  
 Ichthyosiform presentation  
 Erythrodemic presentation  
 
The most common specific cutaneous lesions are maculo-papules, plaques, subcutaneous 
nodules, lupus pernio and scarsarcoidosis (4).  The site of predilection for maculo-papular 
eruptions is the face, anterior chest, extremities, and the mucosa.  Erythema nodosum (EN) is 
the most frequent non-specific cutaneous presentation and is associated with an acute 
presentation, good prognosis and spontaneous resolution (31, 22).  This presentation consists 
of a painful, red and elevated subcutaneous nodule, characteristically on the anterior aspect of 
the legs.  As the nodules involute, residual post–inflammatory hyperpigmentation is seen. 
There is an ethnic difference as these lesions are seen less frequent in Blacks and Asians.EN 
and bilateral hilar lymphadenopathy on the chest x-ray are a constellation of features that is 
termed Löfgren’s syndrome. 
 
Papular lesions and subcutaneous nodules are more often associated with remission of extra-
cutaneous disease at twenty four months, while plaques and, mainly, lupus pernio are 
considered predictive features of chronicity (33, 22).  The majority of cutaneous lesions of 
sarcoidosis are mild and treatment may not be required.  However, lupus pernio (LP) is a 
chronic, disfiguring skin lesion and can have a strong psychosocial impact  (4, 31, 32).  LP is 
frequently associated with upper respiratory involvement and pulmonary fibrosis.  The 
primary pattern arises de novo or from established sarcoid-specific lesions. This characteristic 
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primary pattern of presentation occurs with a raised erythematous or violaceous infiltrate, 
with the site of predilection being the head and face  (33). 
Skin sarcoidosis has an unpredictable natural course  (2). 
ii. Epidemiology 
• Global trends 
 
An increase in reports on case series of sarcoidosis led to better definitions and diagnostic 
tools, improving the determination of incidence and outcome of the disease (12,17, 21, 22, 
24).  Sarcoidosis may appear at any age, with bimodal peaks at age 20 - 40 years  and 40 - 59 
years (18).  African American patients have an increased incidence of 4:1 compared to the 
White population, with a female predominance (8, 10, 14).  Rybicki and colleagues  
conducted a study on a military veteran population which was racially heterogeneous, and 
found the highest incidence in female African Americans compared to Caucasian females (29 
versus 12 per million) (13).  There is an increased familial prevalence, particularly in African 
American patients (34) but genetic associations remain unknown (20).  
 
Skin involvement occurs mainly at the onset of disease.  A study reviewing specific cutaneous 
lesions in southern Europe reported that skin  lesions manifest in 30% of patients with 
sarcoidosis and are subsequently followed by systemic involvement in a period of one month 
to a year  (4). The risk of progression from primarily isolated skin lesions to systemic 
involvement is not known. 
 
• Sub-saharan African Cutaneous Sarcoidosis trends 
Studies on the cutaneous manifestations of sarcoidosis are limited in Africa. The profile of 
sarcoidosis has been studied in Nigeria and Ethiopia.  The most common clinical picture 
reported was that of sarcoidal infiltration of scarification marks.  Facial maculo-papular 
lesions also were frequently present (23, 35, 36). 
 
• South Africa 
The frequency of the skin types described by Jacyk  (17) in Black South Africans showed 
similarities to those in the general population with sarcoidosis. A comparative study of 
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sarcoidosis  (19) conducted among the racial groups in South Africa found an increase in 
frequency and much more florid cutaneous manifestations of sarcoidosis amongst the non-
White population. In addition, a more atypical nonspecific spectrum is reported, including 
hypopigmented, ichthyosiform, mutilating, ulcerative chronic and severe lesions.  In contrast, 
EN (nonspecific) was reported to be the most frequent finding amongst the White population 
in South Africa, as in the European population.  Lupus pernio associated with systemic 
involvement, together with subcutaneous lesions, was amongst the least common in the non-
White community (19).  Studies done in South Africa on the cutaneous spectrum of sarcoidosis 
have been case reports  (37, 38) and a small case series  (39) describing a subset in the spectrum 
of cutaneous sarcoidosis.  The last cohort study was concluded almost two decades ago (17).  The 
pattern of presentation in the Black Africans described as florid and disfiguring is an unusual 
manifestation of cutaneous sarcoidosis (15).  One may argue that there is no statistical 
significance of the findings in the South African literature as these were single case reports 
(38) or small case series  (37, 39) over a short-term follow-up period.  However, these 
associations are important to study further and may represent opportunities for further research. 
 
Sarcoidosis was ranked the 50th most common dermatological disease in 2003 in 
Johannesburg in a survey of dermatological outpatients in the five academic hospitals serving 
the public sector in the Johannesburg area (40).  Other studies on cutaneous sarcoidosis done 
in South Africa demonstrated differences in the disease pattern, frequency, degree and 
laboratory findings (17, 19, 41). However, the paucity of recent epidemiologic studies limits 
the true incidence and prevalence of this disease in South Africa. 
 
1.2.4. Aetiopathogenesis 
Various trigger factors have been implicated as promoting this granulomatous inflammatory 
response. Recently, mycobacteria and proprionibacteria, which demonstrate a similar 
histopathological granulomatous process, have been implicated  (31). However, as the 
microbiology techniques that yield mycobacteria have become more widely available to 
diagnose tuberculosis, it is now clear that tuberculosis is not a variant of sarcoidosis (6). The 
granulomas formed include oligoclonal CD4 T cells that have been stimulated by an unknown 
sarcoidal antigen, giving the characteristic histologic feature of non-caseating granulomas in 
multiple organ systems (5).  The core, highly organized granuloma, comprises macrophages 
and epithelioid cells in 100% of the cases, surrounded by giant cells in 97%, and scanty 
lymphocytes, which are predominantly CD4 positive, in 71% of the cases. Other cellular 
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types include neutrophils associated with necrosis.  Asteroid bodies and Schaumann bodies 
are seen in a minority of cases.  These changes are less sensitive and are nonspecific markers 
of sarcoidosis (42, 43).  Rarely, varying degrees of necrotic changes are found in the 
histopathological specimen (44, 45).  Of note, there are no significant histopathological 
differences found between cutaneous sarcoidosis and extra-cutaneous sarcoidosis (42). 
 
 
1.2.5. Immunology 
The pathogenesis of sarcoidosis involves the contribution of a wide range of cellular 
components of the immune system, including lymphocytes, macrophages and antigen-
presenting cells.  A cascade of reactions mediated and co-ordinated by various cytokines and 
chemokines are implicated in the disease process. Data suggests that a pro-inflammatory 
cytokine, tumour necrosis factor-alpha (TNF-α) in particular, is not only required to stimulate 
the formation of a granuloma in response to an antigen, but sustains the existence of the 
granulomatous process (46, 47).   This observation is an important consideration in the light 
of the commercially available monoclonal antibodies against TNF-α as a therapeutic option 
(46, 48). 
 
 
1.2.6 Diagnosis 
In the early seventies, very few diagnostic indicators were used, i.e., a suspicious lesion, a 
suspicious chest X-ray (CXR) or hand X-ray (HXR), or a granulomatous histological specimen 
which did not exclude other granulomatous aetiological agents (19).  These methods opened gaps 
for misdiagnosis of cutaneous sarcoidosis.  How the diagnosis is made and how it relates to the 
treatment of choice in the 21st century needs further exploration.  
 
The diagnostic process of sarcoidosis is complex; therefore a correct diagnostic workup which 
includes clinical, radiologic, and histopathological evaluation needs to be done.  Histology of 
sarcoidal lesions demonstrates a granulomatous reaction pattern characterized by multiple 
discrete, predominantly epithelioid, granulomas without necrosis, the so-called “naked” 
granulomas, which are surrounded by sparse lymphocytic infiltrate and mild fibrosis  (44, 45).  
 
The definitive diagnosis of cutaneous sarcoidosis has to include: compatible skin and clinical 
or radiological features, together with one or more biopsy specimens that demonstrates non-
caseating granulomas , as well as exclusion of other aetiologies of granulomatous diseases 
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such as tuberculosis or deep fungal infections (6, 10, 22, 28,49). America authors Sanchez et 
al., developed a simple step ladder approach towards the diagnosis of sarcoidosis (32).  This 
approach is easy to use, assists towards making a focused diagnosis, and provides guidance 
that will eliminate unnecessary delays towards a definitive diagnosis.  Figure 1.1 elaborates 
on the step-wise approach to diagnosis of sarcoidosis.  
 
 
Figure 1.1  Step-wise approach to diagnosis of sarcoidosis (adapted from Haimovic A.et al. 
2012 (71)) 
 
Genetic aspects of sarcoidosis supporting the familial predisposition in the context of case 
control study designs  address a component of genetic epidemiology of quantifying the 
familial risk (20).  Harrington et al. described 19% of the African American population and 
86% of Caucasians with a positive family history of sarcoidosis (50).  Even with the current 
advances in the study of genetic components associated with sarcoidosis, the data remains 
elusive. 
 
 
Sarcoidosis is highly likely 
13 
 
1.2.7 The impact of HIV/AIDS pandemic on the clinical manifestation of cutaneous 
sarcoidosis 
Anecdotal reports in recent international literature of the co-existence of sarcoidosis and 
HIV/AIDS describe the relationship of the clinical manifestations of sarcoidosis being 
inversely proportional to the CD4 count  (51-53). However reports fail to demonstrate any 
correlation with the pattern, severity or chronicity of this disease in this population. 
 
 
The granulomatous reaction pattern of sarcoidosis has been implicated to depend on CD4 T–
helper lymphocytes, but infection with HIV depletes these cells and attenuates the expression 
of sarcoidosis.  Morris et al., American authors, conducted one of the largest studies of HIV 
seropositive cases with sarcoidosis in 2003.  The findings strongly suggest that a raised  level 
of cellular immunity is needed for HIV seropositive individuals to manifest the 
granulomatous response to the sarcoid agent, unlike mycobacteria or chronic infection (54, 
55).  The clinical manifestations of sarcoidosis occur either coincidently with, or following, a 
diagnosis of HIV seropositivity.  The CD4 lymphocyte count was recorded as more than 200 
cells/μL at the time of the clinical presentation with granulomatous inflammation. 
 
 
In about 50% of cases initiated on HAART, there is manifestation of an immune 
reconstitution inflammatory syndrome (IRIS) phenomenon (56, 57).  Although rare, clinicians 
should be aware of the appearance of sarcoidosis lesions in HIV-infected individuals whose 
immune systems have improved with the initiation of HAART (51, 53, 58).  The clinical, 
radiographic, and pathologic features of sarcoidosis in the context of pre-existing HIV 
infection are reported to be similar to the well-known features of sarcoidosis in non-HIV-
infected individuals (54). 
 
• South Africa 
More studies are necessary to elucidate the relationship of HIV and cutaneous sarcoidosis 
especially in the South African setting, where 7.1 million people currently live with HIV (70).  
1.2.8 Management 
With the available treatment options, patients can go into remission for long periods, but 
treatment of sarcoidosis still remains a challenge (39).  The decision to initiate therapy in an 
individual with cutaneous sarcoidosis is determined by how extensive or disfiguring the 
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presentation is.  It can also be limited by other co-existing disease entities such as 
hypertension, diabetes and  renal insufficiency,  that increase the side-effect profile of the 
drug used or exacerbate the existing co-morbid condition (e.g. the use of systemic steroids can 
cause hypertension and hyperglycaemia; methotrexate can cause renal toxicity (Table 1.3)).  
A multidisciplinary approach is crucial for optimal management.  There is a paucity of 
double-blinded randomized control studies. However, the first-line standard therapy for mild 
to severe skin lesions includes topical, intra-lesional and systemic corticosteroids. Topical 
steroids or intra-lesional steroids are first-line therapeutics for an isolated or non-threatening 
sarcoidal lesion (59, 60).  Oral corticosteroids are the therapeutic agents that are preferred for 
rapidly progressive cutaneous sarcoidosis eruptions, in combination with topical therapy for 
poorly responsive lesions (30, 61). Other anti-inflammatory and immunosuppressive agents 
may be prescribed as monotherapy or as adjuvant to slowly reduce the dose of corticosteroids 
(34). The table (Table1.3) below highlights the current therapeutic agents available for use. 
 
Table1.3 Cutaneous sarcoidosis treatment (adapted from Heath CR. et al. 2012 (11)) 
Drug therapy Evidence based category Side effects 
Topical 
corticosteroids 
2 Hypopigmentation, thinning of the skin 
Intra-lesional 
corticosteroids 
2 Hypopigmentation, thinning of the skin 
Systemic 
corticosteroids 
2 Short term: Gastric irritation, increased 
appetite, mood disturbances. 
Long term: osteoporosis, hypertension, 
acne, hyperglycemia, Cushing syndrome 
Antimalarial  1 chloroquine 
2 hydroxychloroquine 
Short term: corneal opacity, central 
retinopathy, visual field disturbances. 
Long term: bleaching of hair, 
agranulocytosis. 
Methotrexate  2 Liver toxicity, kidney toxicity, gastric 
disturbances 
Level 1 = prospective clinical study with >20 cases, lacking adequate controls 
Level 2 = small clinical study with < 20 cases with significant design limitations, 
retrospective 
Steroid-sparing agents frequently used are anti-malarial agents and methotrexate  (11). Co-
administration of corticosteroid-sparing agents and topical steroids are beneficial in 
accelerating dose reduction of systemic steroids (32). 
 
A proposed algorithm by an American author, Haimovic, is an easy guide to managing 
patients with cutaneous manifestation of sarcoidosis (31). The latest treatment modalities, 
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including tumor necrosis factor alpha inhibitors (TNF-α inhibitors), have been shown to be of 
benefit in recalcitrant sarcoidosis subtypes (46).TNF-α inhibitors target the release of the TNF 
molecule that plays a role in the formation and sustainability of the non-caseating granuloma 
(46, 47).  The Figure 1.2 elaborates on the management approach proposed. 
 
 
Figure 1.2: A proposed therapeutic ladder for the treatment of skin sarcoidosis (adapted 
from Haimovic  A. et al. 2012 (31)) 
* Intra-lesional steroids 
**Experimental therapy including: laser ablation, surgery; ultraviolet therapy 
***Mycophenolate mofetil 
CS = corticosteroids 
 
1.2.9. Conclusion 
Although recent statistics show a more defined approach in the description of the cutaneous 
spectrum of sarcoidosis, there are still gaps in the South African literature, particularly since 
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the last South African study was published 18 years ago.  Poor access to healthcare, as well as 
migratory patterns, may have had an influence on epidemiological trends of cutaneous 
sarcoidosis in this country.   The patterns, chronicity and severity associated with systemic 
involvement may change as access to healthcare in the post-apartheid era has improved. 
 
CHAPTER TWO 
METHODOLOGY 
2.1. Introduction 
The purpose of this chapter is to provide information on how this investigation was carried 
out.  The target population, sampling, research design, data collection methods, data analysis 
and ethical considerations are discussed in this chapter. 
 
2.2. Study design 
This is a descriptive retrospective study. 
 
2.3. Study setting 
The Division of Dermatology in the Department of Internal Medicine at the University of the 
Witwatersrand in Johannesburg, South Africa, offers dermatological care to patients in a 
number of public hospitals, one of which is Chris Hani Baragwanath Academic Hospital 
(CHBH).  The clinic is staffed by three registrars, one medical officer, a specialist 
dermatologist, two staff nurses and two enrolled nurses. The health personnel are assisted by 
visiting nursing students from CHBH Nursing School.  An average of 400-800 patients a 
month attend the Dermatology Clinic, and skin biopsies are performed on all new patients 
where a definitive clinical diagnosis cannot be made. 
 
2.4. Study population 
The study was conducted at a tertiary academic institution, Chris Hani Baragwanath 
Academic Hospital (CHBH), located in Gauteng. CHBH provides healthcare to a large 
drainage area in the south of Johannesburg (Figure 3) i.e. Soweto and its neighbouring 
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townships, Lenasia and Eldorado Park. CHBH is a 3000+ bed hospital serving a catchment 
population of 1.3million in Soweto, where 40% of the population in Johannesburg resides. 
 
 
Figure 2.1 Map showing the study area (Source: Google Maps) 
 
2.5. Selection criteria and sample size 
This study focused on South African residents who reside in the CHBH drainage area (as 
described above) who presented to the Dermatology outpatient department with cutaneous 
manifestations of sarcoidosis.   The study specifically reviewed the medical records of those 
patients that were seen at the Dermatology outpatient clinic at their first visit and those 
referred from the Pulmonology outpatient clinic with extra-cutaneous involvement and 
suspicious skin lesions suggestive of sarcoidosis.  A total of 100 files of patients of all ages, 
fulfilling the definitive diagnosis of cutaneous sarcoidosis, with or without systemic 
involvement, were included. This study spans from 1991 to 2015.  Further information was 
obtained from the history and clinical findings that were provided for the histology specimens 
submitted to the National Health Laboratory Services (NHLS). 
 
2.6 Data collection (see Appendix A for the data collection sheet) 
Patients were included if the records showed features compatible with a diagnosis of 
sarcoidosis and the exclusion of other granulomatous diseases.  The data extracted also 
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included findings from the history, physical examination and laboratory tests. Some clinical 
characteristics of patient information collected demonstrate the chronicity and severity of the 
disease progression, an evaluation of the number of areas involved, including the extent of 
lung involvement which was assessed by using information from two of the three methods 
(10) used to determine the extent of lung involvement (Appendix A, page 58) i.e. these 
methods included: chest radiography (CXR) findings including radiographic staging and high 
resolution computerized  tomography (HRCT) scans (Appendix A, page 58).   The grading of 
dyspnoea, as a third method to evaluate the extent of lung involvement, was not extracted 
from the records.  In addition, the histopathology data extracted comprised reports by 
designated pathologists who made a clinicopathological conclusion consistent with 
sarcoidosis.  The site of tissue obtained for histological confirmation was recorded, as well as 
the organ systems involved (i.e. skin, lung, eye, lymph node and other organs).   
 
2.6.1 Measurements 
Information regarding patients’ demography (gender, age, race), duration of disease, age of 
onset, occupations, clinical data on the distribution and the extent of disease, treatment 
modality and the type of cutaneous manifestation of sarcoidosis was extracted from the 
patient files and transferred into a data collection sheet (attached).In addition, biopsy data, 
radiological data (chest X-rays (CXR), hand X-rays (HXR), high resolution computerized 
tomography (HRCT)) and pulmonary function tests were recorded.  Particular attention to 
exclude patients with other granulomatous diseases was ensured. 
 
Methods used in histological specimens to exclude other granulomatous disease aetiologies 
included the use of special stains (Periodic acid–Schiff (PAS), Grocott, Ziehl-Neelsen and 
FITE stains) to exclude tuberculosis and deep fungal infections, and the GeneXpert 
polymerase chain reaction test to exclude tuberculosis. Sputum for acid-fast bacilli (AFB), 
where appropriate, was negative. Tissue samples were considered compatible with sarcoidosis 
if they demonstrated non-caseating granulomas without evidence of other granulomatous 
disease aetiologies.  Organ involvement (cutaneous and extra-cutaneous) was determined in 
each patient, based on the information obtained from the records such as history, physical 
examination, and laboratory testing. The radiological findings were recorded as normal or 
abnormal, and the CXR evaluated using the Scadding criteria.  The Scadding criteria, is a 
chest radiographic staging system used in sarcoidosis and is defined as follows: Stage 0: 
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normal chest X-ray; Stage I: hilar lymphadenopathy alone; Stage II: hilar lymphadenopathy 
plus interstitial lung disease; Stage III: interstitial lung disease alone; and Stage IV: lung 
fibrosis.  The findings of HRCT scans, where performed, were noted. Spirometry was 
recorded as obstructive, restrictive or normal. Blood investigations, including complete blood 
count, liver functions, serum angiotensin converting enzyme (ACE) and calcium were 
extracted and interpreted according to the reference ranges of the local laboratory (NHLS). 
Other investigations included electrocardiograms (ECG) and ophthalmological examinations. 
CD4 counts and HIV viral loads were recorded for HIV seropositive patients. 
Chronicity of cutaneous sarcoidosis was determined by examining the clinical outcomes of 
the lesions.  The follow-up was determined with a guide from Marcoval et al. (22) of active 
lesions over a period of more than 24 months. 
 
2.8 Data entry 
Information was collected by the investigator making use of a data collection sheet recording 
the following: year of diagnosis, age at diagnosis, gender, race, occupation.  It was then 
captured into a Microsoft Excel spreadsheet for data cleaning and coding purposes. 
 
2.9 Data analysis 
The data were coded and entered into Microsoft Excel (MS Excel) and later transferred into 
the Statistical Package for IBM Social Science (SPSS) version 21, 2016; for the purpose of 
analysis. Descriptive analyses (means, percentages, frequency, tables and graphs) were 
carried out to summarise demographic characteristics of patients and categorical variables 
such as race, gender, histology, HIV status, organ involvement and cutaneous lesions. 
Bivariate analysis was performed to examine the relationship between independent variables 
(age, gender, and race) and dependent variables (clinical presentations and organ 
involvement). P-values less than 0.05 were deemed significant. Results are presented with 
tables and charts. 
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2.10 Ethical approval and other considerations 
Approval was obtained from the Human Research Ethics Committee of the University of the 
Witwatersrand.  Protocol number: M 150237 (Appendix B).  Data for this research will only 
be for the purpose of this study.  To ensure confidentiality and anonymity of the participants, 
code numbers were used during data processing and reporting. Consent was obtained from the 
Chief Executive Officer and Heads of the Departments of all clinics at Chris Hani 
Baragwanath Academic Hospital. 
2.11 Conclusion 
This chapter provides information on how this study was carried out, whereby the methods 
include the target population, sampling, research design, data collection methods, and data 
analysis.  The following chapter reports the results that were obtained during the conduction 
of the thesis. 
 
 
 
 
 
 
 
 
 
 
21 
 
CHAPTER THREE 
RESULTS 
3.1 Introduction 
This chapter presents the findings of this study. The findings are presented according to the 
study objectives with the use of tables and charts. 
 
 
3.2 Demographic characteristics 
Data were available for 100 patients with cutaneous sarcoidosis during the study period 1991-
2015. Eighty-three participants were women and 17 were men. As shown in Figure 3.1, the 
age range of patients was 20 - 79 years. In males, the age group 40-49 years was the most 
affected, whilst female patients in the age group 50-69 years was most affected.  
 
Figure 3.1: Percentage of patients with cutaneous sarcoidosis by age and sex 
 
3.3 Distribution of patients with sarcoidosis by occupation 
Unfortunately, the majority of patients (n=75) did not have any occupational status recorded, 
making any statistical conclusions regarding occupational associations impossible. 
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Most of the female patients with sarcoidosis were above the age of 45 years.  Ninety-six 
patients were Black Africans and four were Asians, in keeping with the demographics of the 
geographic region served by the hospital. Therefore this study reflects data of Black patients 
mainly. 
 
3.4 Demographic characteristics of patients and clinical cutaneous manifestations 
The most common specific skin lesions were papules and plaques (see Table 3.1). Of the 
enrolled patients, 68 had papules, 28 plaques, 17 subcutaneous nodules, and 11 lupus pernio. 
Only one patient presented with psoriasiform cutaneous lesions. Although there are marked 
differences in the proportion of male to female patients, there appears to be no significant 
differences in the manifestations by gender. Papules (68.8%) and plaques (27.1%) were the 
most common specific cutaneous lesions in Black African patients.  Of the four Asians, only 
one presented with papules, two with plaques and the other presented with scar sarcoidosis. 
 
Table 3.1: Types of cutaneous lesions by gender and race 
Types of cutaneous lesions Total  
n=100 (%) 
Gender Race 
Male 
n=17 (%) 
Female 
n=83 (%) 
Black African n=96 
(%) 
Asian 
n=4 
 (%) 
Papules 68 (68.0) 8 (47.1) 60 (72.3) 67 (69.8) 1 (25.0) 
Plaques  28 (28.0) 5 (29.4) 23 (27.7) 26 (27.1) 2 (50.0) 
Scar 4 (4.0) 1 (5.9) 3 (3.6) 3 (3.1) 1 (25.0) 
Lupus Pernio 11 (11.0) 1 (5.9) 10 (12.0) 11 (11.5) --- 
Psoriasiform 1 (1.0) --- 1 (5.9) 1 (1.0) --- 
Subcutaneous Nodules 17 (17.0) 6 (35.3) 11 (13.3) 17 (17.7) --- 
Hypopigmented Macules 3 (3.0) --- 3 (3.6) 3 (3.1) --- 
Ulcerative 4 (4.0) --- 4 (4.8) 3 (3.1) 1 (25.0) 
Erythrodermic 1 (1.0) --- 1 (1.2) 1 (1.0) --- 
Ichthyosiform --- --- --- --- --- 
Sarcoid (Alopecia) and Nails 3 (3.0) -- 3 (3.6) 3 (3.1) --- 
Prurigo 5 (5.0) 1 (5.9) 4 (4.8) 4 (4.2) 1 (25.0) 
Dactylitis 12 (12.0) 1 (5.9) 11 (13.3) 12 (12.5) --- 
 
 
The study also examined the association between cutaneous manifestation and age. As shown 
in Figure 3.2, about 70% of the age group 45 years and above presented with papules, 
compared to 59.1% of the age group less than 45 years.  There was no statistically significant 
difference between the cutaneous lesions and the age of patients, except for subcutaneous 
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nodules. Patients aged less than 45 years were more likely to present with subcutaneous 
nodules compared to older patients (relative risk 2.7; CI 95% [1.3, 5.4]; p=0.012). 
 
 
 
Figure 3.2: Types of cutaneous lesions by age (years) 
yr = years 
3.5 Extra-cutaneous organ involvement 
This study also examined the patterns, severity and chronicity of cutaneous manifestations in 
sarcoidosis patients and the findings are presented in this section.  Patterns of presentation are 
interpreted in relation to extra-cutaneous involvement, the extent of involvement, the number 
of organs involved, and the outcomes post therapy or in response to therapy.  As shown in 
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Figure 3.3, the most frequent extra-cutaneous organ involvement is lung involvement in53 
cases, eyes 14 cases, bone/joint 10 cases, lymph nodes and the liver 8 cases each, spleen 6 
cases, nervous system and the heart 3 cases each, mucosa 2 cases. Kidney and bone marrow 
were observed in one case each in each organ. 
 
 
Figure 3.3: Extra-cutaneous organ involvement 
 
3.5.1 Number of organs involved 
As indicated in Figure 3.4, 36% of the cutaneous sarcoidosis patients had only skin 
involvement. Similarly, 36% of the cutaneous sarcoidosis patients had two organs involved.  
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Figure 3.4: Number of organs involved 
Of the patients with two organs involved, the skin and lungs were the most common organs 
involved (29 of 36). Table 3.3 below elaborates on the number of organs involved. 
Table 3.3: Patients with three organs involved 
Organs involved Number of patients 
Skin, lymph nodes, and bone and joints 2 
Skin, lungs and eyes 7 
Skin, lungs and lymph nodes 1 
Skin, lungs, and heart 1 
Skin, lungs, bone and joints 3 
Skin, lungs, and spleen 1 
 
 
3.5.2 Patients with four and five organs involved 
Only nine patients had four organs involved. Four percent of the cutaneous sarcoidosis 
patients had five organs involved. 
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3.5.3Association of demographical characteristics and number of organ involvement 
The relationship between demographic characteristics and the number of organs involved was 
examined and the results are presented in Table 3.4.  There was no significance difference in 
number of organs involvement and patients’ age or sex. 
 
Table 3.4: Number of organs involved by age, gender and race 
 Sex Race Age 
Organ 
involvement 
Male 
n=17 
(%) 
Female 
n=83 (%) 
Black African 
n=96 (%) 
Asian 
n=4 
 (%) 
Age 
<45 
≥45 
Only one organ 2 (11.8) 34 (41.0) 36 (37.5) 0 (0.0) 8 (36.4) 26 
(34.2) 
Two organs  10 
(58.8) 
26 (31.3) 33 (34.3) 3 (75.0) 7 (31.8) 29 
(38.2) 
Three Organs  2 (11.8) 13 (15.7) 15 (15.6) 0 (0.0) 4 (18.2) 11 
(14.5) 
Four organs 3 (17.6) 6 (7.2) 9 (9.4) 0 (0.0) 2 (9.1) 7 (9.2) 
Five organs  0 (0.0) 4 (4.8) 3 (3.1) 1 (25.0) 1 (4.5) 3 (3.9) 
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3.5.6 Extra-cutaneous organ involvement by specific type lesion 
The study also examined the association between organ involvement and patterns of 
cutaneous manifestation. The results are presented in Table 3.5.  Of the 53 patients with lung 
involvement, the most common cutaneous pattern was papules (n=39). The second most 
common pattern was plaques (n=20).  Regardless of organ involvement, papules remained the 
most common pattern of clinical presentation as shown in Table 3.5 
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Table 3.5: Extra-cutaneous organ involvement by specific type lesion 
 Lung 
n=53 
LN 
n=8 
Eyes 
n=14 
Nervous 
n=3 
BM 
n=0 
BV 
n=1 
Heart  
n=3 
Bone/joint 
n=10 
Muscle 
n=0 
 
Liver 
n=8 
Spleen 
n=6 
Mucosa 
n=2 
Kidney 
N=1 
Papules n=68 39 4 10 2 0 1 2 5 0 6 5 2 1 
Plaques n=28 20 1 3 1 0 0 0 3 0 2 1 0 0 
Lupus n=11 6 0 0 1 0 0 1 0 0 0 0 1 0 
Scar n=4 3 0 0 0 0 0 0 0 0 1 1 0 0 
Subcutaneous 
n=16 
7 4 3 0 0 0 1 2 0 2 1 0 0 
 
 
LN- lymph node; BM- bone marrow; BV- blood vessel 
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3.6 Clinical patterns of cutaneous sarcoidosis and the chest X-ray findings 
 
Pulmonary involvement was assessed using the method of radiographic staging (Scadding 
criteria) and pulmonary function tests. The majority of cases were classified as Stage 0 or 1 
according to the Scadding criteria. Only four patients were in radiographic Stage 4. The 
patterns of clinical presentation were not associated with the degree of lung involvement. 
Table 3.6 below elaborates. 
Table 3.6: Pattern of clinical presentation by chest X-ray finding 
Cutaneous presentation Staging by CXR (Scadding criteria) 
STAGE: 0 1 2 3 4 
Papules n=58 15 23 9 8 3 
Plaques n=26 4 12 4 4 2 
Scar n=3 1 2 0 0 0 
Lupus Pernio n=8 1 5 1 1 0 
Psoriasiform n=1 0 0 1 0 0 
Subcutaneous Nodules n=17 8 4 3 2 0 
Hypopigmented Macules n=3 0 2 0 1 0 
Ulcerative n=4 0 4 0 0 0 
Erytheodermic n=1 1 0 0 0 0 
Scalp (alopecia) and nails n=2 0 1 1 0 0 
Prurigo n=4 3 1  0 0 0 
Dactylitis n=10 4 2 2 0 2 
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The pulmonary function test results showed that 45 patients had normal lung function. Of the 
41 patients with an abnormal lung function, 19 patients had restrictive lung function, 19 
patients had obstructive lung function, and only 3 patients had mixed pattern lung function. 
There were no records of pulmonary function tests for 14 patients. 
 
3.7 Chronicity of cutaneous sarcoidosis 
Active lesions with progression (worsening) and active lesions with no change (static) while 
on therapy that were found on record were classified as not resolved. Lesions that were 
recorded as absent and then reappear post-therapy were recorded as waxing and waning. Of 
all the patients, there was complete resolution in 28 patients over 24 months, waxing and 
waning in 33 patients, static involvement in 12 patients, and worsening lesions in 2 patients. 
Clinical outcomes could not be determined in 25 patients due to inadequate records.  
 The study also examined the clinical outcomes by patterns of presentation (Table 3.7). Of the 
patients that presented with papules (n=69), there was complete resolution in only 17.  A 
significant proportion of patients that presented with papules had either static involvement (10 
patients), waxing and waning (24 patients), or worsening (2 patients).  
Of the 28 patients presenting with plaques, waxing and waning lesions were the most 
common pattern. However, for the four patients that presented with scar sarcoidosis, there 
was complete resolution in two. Patients that presented with lupus pernio presented with 
waxing and waning or with static lesions. Complete resolution was common only in patients 
who presented with subcutaneous nodules.  
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Table 3.7: Clinical outcomes of sarcoidosis patients according to patterns of presentation 
 
 
The clinical outcomes of cutaneous sarcoidosis patients were examined in relation to the 
number of organs involved. There was complete resolution in 7of the 36 patients with only 
skin involvement. The rest were either waxing and waning or no change (static) in nature.  
Patterns of presentation Clinical Outcomes 
 Wax &wane Static  Worsening Resolved Undetermined 
Papules n=69 24 10 2 17 16 
Plaques n=28 11 2 0 5 10 
Scar n=4 1 0 0 2 1 
Lupus pernio n=11 5 2 0 2 2 
Psoriasiform n=1 0 1 0 0 0 
Subcutaneousnodules 
n=17 
4 1 0 8 4 
Hypopigmented macules 
n=3 
2 0 0 0 1 
Ulcerative n=4 1 0 0 1 2 
Erythrodermic n=1 0 0 0 1 0 
Scalp (alopecia) and nails 
n=2 
3 0 0 0 0 
Prurigo n=5 3 1  0 1 0 
Dactylitis n=12 7 2 0 3 0 
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Of the 36 patients with skin and one more organ involvement, there was complete resolution 
in 10 patients.  However, there was no record to determine clinical outcomes in 14 patients 
with skin and one more organ involvement.  Table 3.8 demonstrates the clinical outcomes of 
sarcoidosis patients based on the number of organs involved 
 
 
Table 3.8: Clinical outcomes of sarcoidosis patients based on the number of organs involved 
No. of systems 
involved 
Outcomes 
 Waxing 
& waning  
Static  Worsening  Resolved Undetermined 
Skin only   n=36 15 7 0 7 7 
Skin +1      n=36 9 3 1 10 14 
Skin + 2     n=15 4 2 1 5 3 
Skin +3      n=9 2 0 0 4 1 
Skin +4      n=4 2 0 0 2 0 
 
Some patients presented with multiple morphologies.  The clinical outcomes of sarcoidosis 
patients based on the number of morphologies were examined and the results are presented in 
Table 3.9. 
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Table 3.9: Clinical outcomes of sarcoidosis patients based on number of morphologies on 
presentation 
No.of morphologies Outcomes 
 Waxing 
&waning  
Static  Worsening  Resolved Undetermined 
One  lesion (n=57) 15 6 2 18 16 
Two lesions (n=31) 11 5 0 8 7 
Three lesions (n=10) 5 1 0 2 2 
Four lesions (n=1) 1 0 0 0 0 
Five lesions (n=1) 1 0 0 0 0 
 
 
3.8 Treatment 
Topical and oral corticosteroids were administered to 35 patients, whilst 24 patients were 
given a combination of topical corticosteroids, oral corticosteroids and an anti-malarial drug.  
A combination of topical and oral corticosteroids, anti-malarials, and methotrexate was 
administered to 10 patients.  Ten patients were given topical corticosteroids only.  Table 3.10 
summarizes the drugs most commonly prescribed. 
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Table 3.10: Treatment combinations administered to patients 
Treatment  No. of patients Percent 
Topical corticosteroids only 10 10.0 
Topical and oral corticosteroids 35 35.0 
Topical corticosteroids and anti-malarial 2 2.0 
Topical and oral corticosteroids and anti-malarial 24 24.0 
Topical and oral corticosteroids, anti-malarial and methotrexate 10 10.0 
Topical and oral corticosteroids, and methotrexate 6 6.0 
Oral corticosteroids only 3 3.0 
Topical and oral corticosteroids, anti-malarial and Azathioprine 3 3.0 
Topical and oral corticosteroids, methotrexate, and Azathioprine 2 2.0 
Topical corticosteroids and methotrexate 1 1.0 
Topical corticosteroids, antimalarial, and Azathioprine 1 1.0 
Topical and oral corticosteroids and Potassium permanganate 2 2.0 
Oral corticosteroids and methotrexate 1 1.0 
 
 
3.9. Histology findings 
Designated pathologists confirmed sarcoidosis in all 100 patients. The summary of the site of 
biopsy is summarized in Table 3.11. 
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Table 3.11: Site of biopsy 
Site of biopsies taken Frequency  Percentage  
Skin  79 79.0 
Skin &extra-cutaneous site 14 14.0 
Extra-cutaneous site only  7 7.0 
 
As shown in Table 3.12, naked granulomas surrounded by a few epithelioid cells were the 
most common presentation (70% of cases). The next common presentation was naked 
granulomas with epithelioid cells and giant cells (41% of cases).  The least common 
histological presentations were granulomas extending to the subcutis (4%) and granulomas 
with giant cells and asteroid bodies (1%). 
 
Table 3.12: Frequency distribution of granulomatous reaction patterns  
Granulomatous reaction pattern Frequency  Percent  
Naked granulomas surrounded by epithelioid cells and few 
lymphocytes 
70 70.0 
Granulomas with fibrinoid necrosis 14 14.0 
Granulomas extending to the subcutis 4 4.0 
Naked granulomas comprising epithelioid cells and giant cells 41 41.0 
Granulomas with giant cells and asteroid bodies 1 1.0 
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The patterns of presentation versus the histological findings are presented in Table 3.13.  The 
histological feature of papules showing naked granulomas surrounded by epithelioid cells 
with a few lymphocytes was the most common presentation, found in 50 of the cases.  
Plaques were the second most common clinical pattern, which was found with naked 
granulomas surrounded by epithelioid cells with a few lymphocytes (n=20).Fibrinoid necrosis 
was seen in 12% of the cases with papules and the least (4%) in cases with plaque  
Table 3.13: Pattern of presentation versus histological results of patients 
Pattern of 
presentation 
Histology patterns 
 Naked 
granulomas 
surrounded 
by epithelioid 
cells and few 
lymphocytes 
Granulomas 
with 
fibrinoid 
necrosis 
Granulomas 
extending to 
the subcutis 
Naked granulomas 
comprising epithelioid 
cells and giant cells 
Granulomas 
with giant 
cells and 
asteroid 
bodies 
Papules n=69 50 12 1 28 0 
Plaques n=28 20 4 1 15 0 
Subcutaneous 
nodules n=17 
10 3 4 6 1  
Lupus pernio n=11 7 4 1 5 0 
Dactylitis n=12 9 1 0 4 1 
Psoriasiform n=1 0 0 0 1 0 
Hypopigmented 
Macules n=3 
2 0 0 3  0 
Ulcerative n=4 3 0 1 1 0 
Erythrodermic n=1 1  1 0 0 0 
Scar n=4 2 0 1 1 0 
Scalp (alopecia) 
and nails n=3 
3  1 0 0 0 
Prurigo n=5 4 0 0 2 0 
 
 
3.10 Sarcoidosis in people living with HIV 
Of the 100 patients included in this study, 12 were living with HIV infection.  All were 
female and Black African.  Their age ranged from 21 to 39 years. Seven were diagnosed 
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between 2010 and 2014, whereas only three of them were diagnosed between 2003 and 2005. 
At diagnosis, their CD4 counts were low (mean 248 cells/mm3),but increased as their sarcoid 
disease evolved.  All on HAART, and those with initial high viral loads responding to 
antiretroviral treatment displayed concomitant progression of their sarcoidosis. Four had only 
skin involvement, six had both skin and lung involvement, one had skin, lung and eye 
involvement and another had disease involving the skin, lungs, bone and joints.  Five 
presented with papules and plaques; three had papules only.  One presented with 
erythroderma, and another presented with lupus pernio, papules, and subcutaneous nodules. 
Their calcium levels were normal, both before and after therapy.  Three had chest X-ray 
changes and three had only skin involvement. The remaining patient, who was initially 
recorded with skin only involvement, had Stage two chest radiographic changes. The chest x-
ray reports of the six who had skin and lung involvement, indicated that two had Stage three 
radiographic changes, and four had Stage one radiographic changes. 
 
3.11 Summary 
It is important to describe a sample population in terms of its demographics and clinical profile, in 
order to know the population better and to be able to establish areas of concern and areas for 
further research.In this study we have managed to identify the demographics of the population 
group most affected by cutaneous sarcoidosis (Black females older than 45 years of age).  Patterns 
of presentation of cutaneous sarcoidosis have been described and the pattern of progress in 
patients who have both HIV and cutaneous sarcoidosis has been noted and remarked on.  The next 
chapter entertains a discussion on the study findings, explores the limitations and makes 
recommendations.  
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CHAPTER FOUR 
SUMMARY OF FINDINGS, DISCUSSION, CONCLUSION 
 
4.1 Introduction 
This chapter presents a discussion of the study findings, conclusions and recommendations. 
The discussion is based on the study objectives and attempts are made to explain the key 
findings of the study. Where necessary, the findings of this study are compared to previous 
studies on cutaneous sarcoidosis. 
 
4.2 Summary of findings 
The key findings of this study are summarised as follows: 
• Cutaneous sarcoidosis disease was more common in females than males. 
• Cutaneous sarcoidosis disease was more common in older females above the age of 45 
years. 
• The patterns of cutaneous sarcoidosis were predominantly papules and plaques. 
• The lung was the most commonly affected extra-cutaneous organ. 
• The Scadding staging of the lungs in patients with cutaneous sarcoidosis was mainly 
zero and one. 
• There was complete resolution of cutaneous sarcoidosis in only 28 cases over 24 
months.  
• Of the patients that presented with papules (n=69), there was complete resolution only 
in 17 of them. The clinical course of a significant proportion of patients that presented 
with papules was static (10 patients), waxing and waning (24 patients) or worsening (2 
patients).  
• Of the 28 patients that presented with plaques, waxing and waning was the most 
common outcome. However, of the four patients that presented with scar sarcoidosis, 
there was complete resolution in two. Waxing and waning and static were the common 
outcomes of patients that presented with lupus pernio. Complete resolution was 
common only in patients who presented with subcutaneous nodules.  
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4.3 Discussion of results 
This study evaluated the spectrum of cutaneous manifestations of sarcoidosis among patients 
attending the Chris Hani Baragwanath Academic Hospital Dermatology outpatient clinic from 
1991 – 2015.Studies on cutaneous sarcoidosis in the South African setting are limited.  
Besides the Mosam and Morar study in 2004, which focused only on recalcitrant patterns, the 
only reported work on the spectrum of cutaneous sarcoidosis in South Africa was conducted 
in 1999 by Jacyk et al. (17, 39).  The current study provides a detailed description of the 
various patterns, severity and chronicity of cutaneous sarcoidosis over two decades.  This 
study also examines the co-morbidity of HIV/AIDS and cutaneous sarcoidosis. 
Results presented below are a summary of the main findings in an attempt to answer the 
research questions, with a focus on both the specific and global findings, and what, in 
particular, was uncovered that is new to the body of existing knowledge on cutaneous 
sarcoidosis in South African patients. Some findings had to be interpreted with caution, since 
the sample examined and analysed was a randomly selected cohort of patients seen between 
1991 and 2015, and does not reflect the total number of patients who presented with the 
disease during this period. 
 
4.3.1 Where are we today? 
 
It appears that cutaneous sarcoidosis was first recognizedin the nineteenth century; due to a 
lack of a standardised investigative tools at that time;it is not possible to confirm this, as 
investigators relied on the clinical and unique histological appearance of this disease entity 
(1). It is only in the mid-twentieth century that radiological findings were used when patients 
presented with cutaneous lesions, and lung disease was suspected  (6, 62).  In the twenty-first 
century (ACCESS Research group, 1999) (6), high resolution computerised tomography 
became easily available and exposed the X-ray’s limitations  (6).  With an increased incidence 
of tuberculosis in Africa  (63),it became apparent that this granulomatous disease had some 
histological resemblance to sarcoidosis. This made it difficult to differentiate between the two 
pathologies. But with the advance in diagnostic tools, it became possible to exclude other 
granulomatous conditions  (42, 64, 65). 
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In this study of cutaneous sarcoidosis, all patients were confirmed by biopsy. Some also had 
radiological features of intrathoracic sarcoidosis.  All had compatible clinical presentations 
and exclusion of other granulomatous diseases.  
4.3.2 Correlations between demographic characteristics and patterns of cutaneous 
sarcoidosis 
In answer to the research question of whether there were correlations between demographic 
characteristics and cutaneous patterns of sarcoidosis, the researcher was able to confirm the 
following: 
• Cutaneous sarcoidosis was more common in females than in males. 
• Cutaneous sarcoidosis was more common in older women (above the age of 45 years) 
than in younger women. 
In this study, the peak incidence of cutaneous sarcoidosis was in the age group of 50 to 69 
years and is relatively compatible with recent epidemiology studies (14, 21). Although there 
is no consensus or evidence for the factors causing the increase in age, which has been shown 
in international studies, the hypothesis made here suggests hat changes in the practice and use 
of diagnostic imaging technology could account for the higher incidence in older women. 
Another proposed reason for the high incidence in older women is that they may seek 
professional help for physical disorders more willingly and frequently than younger women 
do. This speculation prompts a need for a study. 
The predominance of Black females in this study is similar to the findings in literature 
globally (8, 10). Of note is the fact that the women were over 45 years of age. Apart from the 
role of improved diagnostic tools, the increased tendency for older women to develop skin 
lesions maybe related to the lack of exposure to endogenous female hormones in older 
women. Hence being pre-menopausal may confer a reduced risk of sarcoidosis (66, 67). The 
lack of evidence for this conclusion, however, makes this speculation. 
 
A supportive hypothesis which may contribute to the high female to male ratio includes the 
possibility that females have a greater tendency than males to observe their body or skin for 
these type of lesions (14, 27).  
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4.3.3 Patterns, severity and chronicity of cutaneous manifestations of sarcoidosis in 
patients 
In an attempt to answer the research question regarding patterns, severity and chronicity of 
cutaneous sarcoidosis, the researcher was able to confirm that  
• the patterns of manifestation were predominantly papules and plaques; 
• skin and lungs were the most commonly affected organ systems; 
• the Scadding staging of lung disease was mainly zero and one. 
Recognition of specific lesions is important as they provide clues for diagnosis. Skin lesions 
are easily accessible to use as tissue specimens to evaluate for definitive histological 
diagnosis; moreover, a punch biopsy is a simple technique to learn and provides a high 
diagnostic yield. 
Skin lesions often appear at the onset of the disease, but may appear at any stage (31, 32).In 
this study, apart from the skin, the most frequent extra-cutaneous organ involvement was the 
lungs (53 cases),followed by eyes (14 cases) and bones/joints (10 cases); the least affected 
was bone marrow and kidneys. In a recent study by Marcoval et al., it was concluded that 
specific cutaneous lesions did not have a predictive factor for the disease severity and 
prognosis (22, 27).  However, there is an exception with erythema nodosum, a non-specific 
pattern of presentation of cutaneous sarcoidosis. It is associated with a good outcome. Lupus 
pernio, a more specific pattern of presentation, is associated with severity and chronicity of 
cutaneous sarcoidosis (17, 27, 32).  In this study, none of our patients presented with 
erythema nodosum.  However, the subcutaneous pattern of presentation had a p-value = 
0.012. It is reported in the literature that due to a limited number of case reports, the 
characteristics of subcutaneous sarcoidosis in relation to systemic disease have not been 
elucidated  (32).  The significant finding in this study on the subcutaneous patterns of 
presentation is similar to the findings of the current literature.  A recent study in America 
reported on twenty-one cases and found that this form of cutaneous sarcoidosis has no 
correlation with severe systemic involvement and has a relatively good outcome. The strength 
of the American study was the significant follow-up period of 32 years  (68).  Literature from 
the east of Africa (Ethiopia) and the west of Africa (Nigeria) reports that the pattern of 
presentation mostly demonstrated subcutaneous nodules and scar sarcoidosis respectively (35, 
36); these were associated with better prognostic outcomes (32). 
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Regardless of the number of organs involved, papules were the most common pattern of 
clinical presentation demonstrated in this study. This concurs with findings globally. Some 
authors report that this type of specific cutaneous lesion does not determine the severity and 
chronicity of this disease entity (22, 32). This seems to be confirmed in this study, because in 
a number of patients the clinical presentation was of one type of lesion co-existing with 
another, i.e., poly-morphology (papules with plaques, papules with lupus pernio). It is up to 
the individual clinician’s discretion to determine which lesion forms the most predominant 
pattern. In a study conducted by Mañá and colleagues, a correlation was found between 
specifically papular lesions with an acute form of sarcoidosis, which included involvement of 
other organs (hilar lymphadenopathy, peripheral lymphadenopathy, parotid enlargement, EN, 
and acute uveitis); this form usually resolved within two years  (3, 32).   
 
Regarding chronicity of the presenting patterns, the following is found: 
In answer to the research questionregarding chronicity, a significant proportion of patients 
with papules (24.6%) and subcutaneous lesions (100%) are frequently associated with 
complete resolution of the lesions.  Apart from having a patient profile with papules that may 
resolve completely, on the contrary papules can be  (36 cases) persistent.  Similarly patients 
who presented with lupus pernio had chronic persistent lesions.  
Our population sample is predominantly Black Africans who presented most frequently with 
papules and plaques. Whether these features of presentation may be attributed to early 
diagnosis or management factors or whether the minimal presence or absence of other 
aetiologies causing granulomatous changes may have been misdiagnosed, cutaneous 
sarcoidosis remains to be further investigated. 
 
4.3.4 Histopathological findings of biopsy specimens of cutaneous lesions of sarcoidosis 
Regarding the histopathological findings of biopsy specimens, and taking into consideration 
the frequent clinical presentation of papules, the histological patterns which were seen most 
frequently, were classic naked granulomas, in 70% of the cases. Only 12% had findings of 
fibrinoid necrosis, similar to the histological findings described in Black South Africans in the 
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literature almost two decades ago by Jacyk, and earlier by Benatar  (17, 19). Perhaps 
improved access to care and earlier diagnosis and treatment interventions now play a role in 
influencing the pattern of presentation, since the natural course of the disease may be changed 
or halted with better access and earlier diagnosis. The notion of advanced and mutilating 
patterns associated with Black Africans and African Americans race could have been 
influenced by late presentations at first visits to outpatient clinics, which in turn could have 
been influenced by racially prejudiced health care policies at the time. These factors prevailed 
right through the eighteenth, nineteenth and early twentieth century. The current findings 
regarding manifestation of the disease entity at first visit may well be strongly influenced by 
better access and earlier presentation.  
 
4.3.5 Association between HIV infection and cutaneous or systemic sarcoidosis 
The last research question posed at the outset of this study was the question of a possible 
correlation between manifestations of cutaneous or systemic sarcoidosis and the presence of 
HIV infection. In this study, people living with both HIV and sarcoidosis interestingly 
demonstrated an inversely proportional association of the disease entity with the CD4 count. 
Disease progression is noted with CD4 increments that occur after initiation of therapy.   
Similarly, those with high viral loads experienced progression of sarcoidosis astheir viral 
loads declined with HAART.  Although half of the patients (six cases) had more than one 
organ involvement (skin and lung involvement), there was no correlation between the 
Scadding stage and lung function, as 2 patients had normal lung function tests with Stage 3 
chest X-rays. 
The clinical patterns of sarcoidosis in the HIV-positive patients did not differ from the non-
HIV infected individuals reported globally, including in the histological findings  (69). Some 
reports in the literature do, however, describe a challenge in the management of cutaneous 
and systemic sarcoidosis where an IRIS is present  (53, 56). 
There is a need for further studies on the coexistence of HIV/AIDS and sarcoidosis. Clarity of 
the immunological relationship needs to be investigated further and more patient reports 
described. There is opportunity to expand such information into a case series.  
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4.4 Limitations 
Limitations are presented here in list form for clarity: 
• Many clinical records were incomplete. 
• Some patients were excluded because their files were missing. This limited the sample 
size. The small sample size hindered the ability to make significant statistical associations.  
• The data was dependent on how well clinical and laboratory information was recorded. 
• The study was conducted for outpatients only.  It would have been interesting to see the 
differences in presentation between inpatients and outpatients, to give a broader picture.  
 
• Patient records from this study included patients from Dermatology and Respiratory 
outpatient clinics only – this does create a bias for patients with lung involvement as an 
extra-cutaneous manifestation.  
 
• This study, which was conducted with records from 1991- 2015 that had not been 
collected consecutively, limited the author from obtaining data regarding incidence and 
changes in trends. 
 
 
4.5 Conclusion 
The study aimed at describing the cutaneous patterns of sarcoidosis in the population that 
presented at the outpatient Dermatology clinic at Chris Hani Baragwanath Academic Hospital. 
This was a retrospective review and the first, to my knowledge, to describe this population at 
CHBH.  Further research and collaboration with other countries in southern Africa is 
recommended for a more significant and statistically relevant contribution to the spectrum and 
management of this rare disease entity. 
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APPENDIX A (Data collection sheet) 
 
DATA COLLLECTION SHEET  PATIENT CODE: ------------ 
Age:…………………………………………………………………………………………………. 
Sex:
…………………………………………………………………………………………………. 
Race:……………………………………………………………………………………………… 
Occupation:…………………………………………………………………………………… 
Histological confirmation of sarcoidosis……………….Year of diagnosis:……………………  
Type of organ specimen: skin  non-skin  specify type of viscera:……….. 
For the following, if yes, give details of histological findings:……………………………………………………………………… 
Granulomatous 
reaction pattern 
Yes  No  Mixed  
Naked granulomas 
surrounded by 
epithelioid cells and 
a few lymphocytes 
   
Granulomas with 
fibrinoid necrosis  
   
Granulomas 
extending to the 
subcutis 
   
Naked granulomas 
comprising 
epithelioid cells; 
giant cells  
   
Granuloma with 
giant cells and 
asteroid bodies 
   
Other    
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Co-morbidity:                              
 
HIV status                             Reactive Non-reactive Unknown 
 
 HAART therapy          yes:       no:   
 
 
CD4: Before HAART            Current  
Viral load: Before HAART   Current:  
 
 
 
 
Organ Involved:  Cutaneous involvement:  Extra-cutaneous involvement:                                         
 
Yes    
No    
 
Interval between diagnosis of sarcoidosis and eruption of skin lesions:……………………………………………… 
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 (Body map for back and front)        
 
 
Documented cutaneous lesion:                                                                 
Specific skin lesions  Non-specific skin lesions 
Distinct lesions Non-distinct lesions Erythema nodosum 
Papules  Subcutaneous  nodule Calcification 
Plaques Hypopigmented  macules Prurigo 
Lupus pernio Ulcerative sarcoidosis Dactylitis 
Scar sarcoidosis Psoriasiform lesions  
 Alopecia and nail sarcoidosis  
 Ichthyosiform  presentation  
 Erythrodemic presentation  
 
Tattoo reactions:  other:……………………………………………………………… 
 
No. of morphology per lesion: 
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Lesion  No. 
  
 
 
Associated                  Pain:  Pruritus:  
 
Investigations conducted: Time commenced: before treatment           after treatment   
 
Tested normalresultsabnormal result: - raised: low:  
  
Full blood count:                                                         ……………   ……………. 
Urea, electrolytes and                                            …………………   …………….              
Creatinine                                                                                     ....................   ............... 
 
Liver function test:                                                      ……………   ……………. 
                                                                                                            ……………   ……………. 
Serum calcium:                                                            ……………   ……………. 
 
Serum ACE:                                                                     ...…………   …………… 
                                                                                                              ……………   ……………. 
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                                                                    Chest radiography:…………………..  
                                                                                                                                                     …………………………grade: zero 
                                                                                                                                             .………………………grade: one 
                                                                                                                                                     .....……………………grade: two 
..………..……….……grade: three 
    …..……….…………….grade: four 
  
Investigations conducted:   Tested  normal results abnormal result:- raised:  low: 
 
 
Hand radiography:                                     osteolytic changes         ………   ……… 
  
Pulmonary function tests:                                                              ……………   ……………. 
                                                                                                                                ……………   ……………. 
 
Electrocardiography:                                                                         ……………   ……………    
                                                                                                                                 ……………   ………….. 
Ophthalmology examination:                                                         ……………   ………….. 
                                                                                                                                ………………   …………. 
Tuberculin Test:                                                                                 …….………   …………… 
                                                                                                                                 ……………   …………….  
Other:  specify:……………………                                                          ……………   …………… 
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Treatment options: 
Name  Dose  Duration  Discontinued/reason 
    
Treatment response: excellent       good          fair             poor    
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